SPINRAZA® is indicated for all patients with 5q‑associated SMA1
The SPINRAZA® clinical trial programme included 346 patients aged from newborns to young adults with SMA who received SPINRAZA® for up to 5 years1
NURTURE
study
published!
Discover the efficacy of
pre-symptomatic
SPINRAZA® treatment in
infants with genetically
diagnosed SMA
The largest and the most diverse real-world study of SPINRAZA® in adults with SMA published!
The Lancet Neurology publication adds to the growing body of published evidence demonstrating the clinical benefit of SPINRAZA® specifically in adults.
SPINRAZA® is indicated for all patients with 5q‑associated SMA1
The SPINRAZA® clinical trial programme included 346 patients aged from newborns to young adults with SMA who received SPINRAZA® for up to 5 years1
NURTURE
study
published!
Discover the efficacy of
pre-symptomatic
SPINRAZA® treatment in
infants with genetically
diagnosed SMA
The largest and the most diverse real-world study of SPINRAZA® in adults with SMA published!
The Lancet Neurology publication adds to the growing body of published evidence demonstrating the clinical benefit of SPINRAZA® specifically in adults.

WATCH THE VIDEO TO DISCOVER MORE ABOUT SPINRAZA®

Explore SPINRAZA® highlights

Mechanism of action
SPINRAZA® has a well-defined, targeted mechanism of action that increases production of full-length, functional SMN protein in the central nervous system1
Clinical resources
Exclusive clinical resources including latest SPINRAZA® data, motor function measures, videos, and a treatment scheduling tool
SPINRAZA® patients
Discover real SPINRAZA® patients and learn about the Together in SMA patient support programme
Clinical resources
Exclusive clinical resources including latest SPINRAZA® data, motor function measures, videos, and a treatment scheduling tool

References:
1. SPINRAZA® Summary of Product Characteristics.
2. Biogen JP Morgan 2020 Presentation. Available at: http://investors.biogen.com/static-files/ad405cb6-f526-4d2a-9d4a-2318b46dea43. Accessed: January 2020.